Recombinant lubricin may feature in future treatment options for CACP patients, although clinical studies are required and technical problems regarding local delivery must be overcome [16]. This evidence concerns the gene PRG4 and camptodactyly-arthropathy-coxa vara-pericarditis syndrome.